Article Information
History
- January 14, 2022.
Article Versions
- Version 1 (August 23, 2021 - 18:04).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- CVD-COVID-UK consortium,
- Writing committee,
- William N Whiteley, FRCP (Chair)1,2,#,
- Samantha Ip, PhD3,
- Jennifer A Cooper, PhD4,
- Thomas Bolton, PhD3,
- Spencer Keene, MSc3,
- Venexia Walker, PhD7,
- Rachel Denholm4,
- Ashley Akbari, MSc9,
- Efosa Omigie, BEng MSc10,
- Sam Hollings, PhD10,
- Emanuele Di Angelantonio, FRCP3,13,
- Spiros Denaxas, PhD14,
- Angela Wood, PhD*,3,
- Jonathan A C Sterne, PhD*,16,17,18 and
- Cathie Sudlow, FRSE*,19
- 1Centre for Clinical Brain Sciences, University of Edinburgh
- 2Nuffield Department of Population Health University of Oxford
- 3Department of Public Health and Primary Care, University of Cambridge
- 4Bristol Population Health Science Institute, University of Bristol
- 7Bristol Medical School: Population Health Sciences, University of Bristol
- 9Population Data Science, Health Data Research UK, Swansea University
- 10NHS Digital
- 13NIHR Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge
- 14Institute of Health Informatics, University College London
- 16Department of Population Health Sciences, University of Bristol
- 17NIHR Bristol Biomedical Research Centre
- 18HDR UK South West
- 19BHF Data Science Centre, Health Data Research UK
- ↵#Corresponding author Email: william.whiteley{at}ed.ac.uk, Telephone: 07811113610
↵* Drs Wood, Sudlow and Sterne contributed equally
Posted January 14, 2022.
Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: whole population cohort study in 46 million adults in England
